Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
FPX Nickel and JOGMEC Delineate Multiple Awaruite Nickel Targets at the Expanded Klow Property in British Columbia
